Benefit from anthracyclines in relation to biological profiles in early breast cancer.
about
Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guidelinePrognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients.Biologic subtype is a more important prognostic factor than nodal involvement in patients with stages I and II breast carcinomaImpact of body mass index (BMI) on the prognosis of high-risk early breast cancer (EBC) patients treated with adjuvant chemotherapy.The Predictive Value of PITX2 DNA Methylation for High-Risk Breast Cancer Therapy: Current Guidelines, Medical Needs, and Challenges.Effect of antitumor treatments on triple-negative breast cancer patients: A PRISMA-compliant network meta-analysis of randomized controlled trials.Androgen and oestrogen receptors as potential prognostic markers for patients with ductal carcinoma in situ treated with surgery and radiotherapy.Is Ki67 still a powerful ally in predicting the clinical benefit of anthracyclines for the adjuvant treatment of early breast cancer?Ki-67 as a Prognostic Factor in Feline Mammary Carcinoma: What Is the Optimal Cutoff Value?
P2860
Q26853619-CAA95C6E-9D78-482E-A0DE-BEF2BE0DEAD0Q27853207-D7F34591-B836-4C1E-A30B-831CCAB18BF9Q36476168-8C6B0148-C816-4D64-A8CA-04EB8CE35C7CQ39557649-A3A03156-5FEE-422B-BAB2-7F80325B2D59Q43375967-1308AFCC-F9AD-47F7-9206-350E91545F44Q47121796-F89DEEDE-2283-4EDF-AE5E-731E546BDE0BQ48201952-97ED6634-2C2D-407A-853C-904A369DCD9FQ48299134-6B0496D9-D287-4301-947B-030CFB0865A3Q51015726-BFDCAF98-3427-4F3E-B0DB-412E75216A0E
P2860
Benefit from anthracyclines in relation to biological profiles in early breast cancer.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Benefit from anthracyclines in relation to biological profiles in early breast cancer.
@en
Benefit from anthracyclines in relation to biological profiles in early breast cancer.
@nl
type
label
Benefit from anthracyclines in relation to biological profiles in early breast cancer.
@en
Benefit from anthracyclines in relation to biological profiles in early breast cancer.
@nl
prefLabel
Benefit from anthracyclines in relation to biological profiles in early breast cancer.
@en
Benefit from anthracyclines in relation to biological profiles in early breast cancer.
@nl
P2093
P50
P1476
Benefit from anthracyclines in relation to biological profiles in early breast cancer.
@en
P2093
Amelia Tienghi
Andrea Rocca
Angelo Paradiso
Dino Amadori
Donata Casadei Giunchi
Laura Medri
Lorenzo Gianni
Luigi Serra
Marina Faedi
Mario Brandi
P2888
P304
P356
10.1007/S10549-013-2819-0
P407
P577
2014-01-01T00:00:00Z